biotech stocks to buy now

This month the American Society of Clinical Oncology held its annual meeting in Chicago, which brought about more attention to the healthcare sector and biotech stocks. The recent deal between Merck and Tilos Therapeutics has sparked increased enthusiasm within the industry.  The takeover will give Merck control of a pipeline of cancer, fibrosis and autoimmune programs targeting the latent TGFβ complex.

Cancer research remains one of the most critical areas of focus for most investors. This is simply due to the fact that if a company can come up with a truly path-breaking product, then the potential for growth could be significant. With this in mind, here are four biotech stocks to watch on Tuesday.

Small Cap Biotech Stocks Take Center Stage

GT Biopharma (GTBP) has followed suit with a clear focus on immune diseases.  The company’s lead treatment, GTB-1550 is a novel multi-target directed therapy for the treatment of chemotherapy-refractory B-cell malignancies, including Non-Hodgkins Lymphoma and Leukemia.  “GTB-1550 has shown positive results in its two Phase I-II clinical trials in advanced cancer patients who have failed all other therapies, and we are now planning to proceed with a Phase II clinical trial,” explained Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma.

Mr. Cataldo took the reigns on GT Biopharma earlier this year.  He is the founder of the company and one of the key leaders within the industry. His past successes include being the founder and previous CEO of Iovance Biotherapeutics. Anthony Cataldo was able to grow Iovance early on, and the company currently holds a market cap of over $2 billion with a share price above $19 per share.

In addition to the above, the company’s therapy has also shown that it could target HIV infected cells in the University of Minnesota’s preclinical testing. Not only that but in specific tests, data showed that HIV-infected targets that express the HIV envelope on their surface could be eliminated. As the company stated, “The HIV TriKE’s possibility to kill the HIV virus would solve a massive economic burden as well as stop infected patients from spreading the disease.”

Adding to this list of novel biotech stocks to watch, Histogenics Corporation (HSGX) is targeting a pipeline of therapies to treat rare eye diseases.  In April, the company announced a deal with Ocugen Inc. to ultimately take over the company. Ocugen was founded by Pfizer’s Shankar Musunuri and University of Colorado professor Uday Kompella. According to reports, once the merger is complete, Ocugen will try to sell Histogenics’ NeoCart, which is its regenerative treatment designed to treat knee cartilages. HSGX shares saw a jump on Tuesday to highs of nearly $0.23 and have been in an uptrend for the last three trading sessions. 

“Since Ocugen’s founding, we have sought to develop innovative therapies to treat rare and underserved eye diseases through a combination of therapeutic approaches that utilize small molecules, biologics, and gene therapies,” said Shankar Musunuri, Ph.D., M.B.A., Chairman, Chief Executive Officer and Co-Founder of Ocugen.

Big Moves On Penny Stock News

Further to the focus on eye care, NovaBay (NBY) stock has taken on a bright light this week. Since making headlines on Monday, shares of the company have jumped from a close of $0.32 last Friday to highs of $4.78 during Tuesday’s premarket session.  This move of nearly 1,400% comes as the company reported that its Avenova eye-care product is now available without a prescription on Amazon.com through its new direct-to-consumer online channel.

“While prescription Avenova continues to be available through retail pharmacies and direct in-office sales by certain eye care specialists, patients and physicians have asked for greater accessibility to the product,” said NovaBay Chief Executive Justin Hall. “In response, we are launching our new U.S. direct-to-consumer channel, which is a significant step in ensuring easy access at an affordable price.”

A Pop & Drop For Others?

Shares of SINTX Technologies, Inc (SINT) have also begun to rally this week.  The move has come after announcing the renewal of its lease with Portfolio Investments at Centrepointe Business Park for a five-year term. Shares are up by more than 50% since Monday afternoon. 

Dr. Sonny Bal, President & CEO, said, “This is a milestone for SINTX. We have right-sized our operations, and the significant cost savings from the building lease will allow SINTX to focus on scaling up our manufacturing, and invest further in R&D activities.”

As the company explains, “The core strength of SINTX Technologies is the research and development of medical-grade silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride spinal implants in its FDA registered and ISO 13485 certified manufacturing facility for CTL-Amedica, the exclusive retail channel for silicon nitride spinal implants.”

Finally, Midatech Pharma Plc (MTP) saw its stock rise on Tuesday morning.  After closing the previous week near June lows of $1.20, MTP shares have jumped as high as $1.73 this week.  The move comes after the company received a patent titled “Nanoparticle Delivery Compositions.” These will specifically be used to target biologically active agents in the central nervous system.

The company itself focuses on patients with rare and serious cancers. Furthermore, the company’s therapies look to improve bio-delivery and bio-distribution of medicines or agents to areas of the body where they are needed and can exert their actions in an effective, safe, and precise manner.

biotech stock to buy 2019
Pursuant to an agreement between MIDAM VENTURES, LLC and GT Biopharma, Midam was hired for a period from 06/07/2019 – 7/07/2019 to publicly disseminate information about GT Biopharma including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of GT Biopharma in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

The $40 Billion Dollar Content Gold Rush

Apple, Disney, Netflix, Amazon, NBC, Hulu & More are All Competing Within the Global Video Streaming Market and They All Need the Same Thing…

1 Biotech Stock is Positioning Itself for Success

Biotech has always been one of the best performing sectors in the market. A number of biotech stocks have produced life-changing returns because of their treatments and opportunities. You wont believe what this 1 stock is doing…

What Curing Cancer & HIV Could Mean for This Company, Its Investors & The World!

The opportunity for companies within this sector is massive we are now talking about an industry that is currently worth over US$ 100 billion with the potential in the next 6.5 years to be worth over US$ 200 billion.

1 Stock is Positioning to Disrupt a Billion Dollar Industry Creating Opportunity & Saving Lives

The Weapons Detection market is expected to grow to nearly $7.5 billion by 2025 and for investors, it could signal big opportunities.